- Burkitt's lymphoma
- Chronic lymphocytic lymphoma
- Cutaneous T-cell lymphoma
- Erdheim-Chester disease (ECD)
- Hodgkin's lymphoma
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Waldenstrom macroglobulinemia
Stephen J. Schuster, MD
About me
- Director, Lymphoma Program
- Director, Lymphoma Translational Research
- Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research
My education and training
- Residency: Pennsylvania Hospital
- Fellowship: Thomas Jefferson University Hospital
- Fellowship: Pennsylvania Hospital
Spoken languages
Reviews
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 1989
- Hematology, 1986
- Internal Medicine, 1984
- American Association for Cancer Research, National
- American Society of Clinical Oncology, National
- American Society of Hematology, National
- Eastern Cooperative Oncology Group (ECOG), National
- Penn Bone Marrow Transplant and Stem Cell Transplant Program
- Penn Cellular Therapy and Transplant Program
- Penn Hematological Malignancies (Blood Cancer) Program
- Penn Lymphoma Program
- Recognized annually in Philadelphia Magazine's Top Docs issue from 2010 through 2025
Treatments and conditions
Research
Publications
Wudhikarn, Kitsada. Bromberg, Maria. Brower, Jamie. Seshan, Venkatraman. Bachanova, Veronika. Ahmed, Sairah. McGuirk, Joseph P. Manu, Gurusidda. Maziarz, Richard T. Oluwole, Olalekan O. Schuster, Stephen J. Porter, David L. Bishop, Michael R. Riedell, Peter A. Perales, Miguel-Angel. Dahi, Parastoo B. Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. , Blood Adv., 10(18): 2026,6188-6197
Paruzzo, Luca. Chong, Emeline R. Chong, Elise A. Zheng, Zhixuan. Guruprasad, Puneeth. Landsburg, Daniel J. Nasta, Sunita D. Stella, Federico. Ramasubramanian, Ranjani. de Souza, Vitor B. Alkhatib, Mohannad H. Ho, Matthew. Imparato, Antonio. Chen, Gregory M. Siegel, Don L. Plesa, Gabriela. Dai, Anlan. Mackey, Shane. Das, Priyamvada. Michener, Peter. Jadlowsky, Julie. Bushman, Frederic D. Patel, Vrutti. Carturan, Alberto. Napier, Ellen B. Gonzalez, Vanessa E. Jarocha, Danuta. Xu, Rong. Levine, Bruce L. Porazzi, Patrizia. Frey, Noelle. Porter, David L. Svoboda, Jakub. Fraietta, Joseph A. June, Carl H. Schuster, Stephen J. Ruella, Marco. Decade-long persistence of CD19 CAR T cells in B cell lymphomas. , Nat Med., 32(9): 2026,3276-3287
Noll, Julia Han. Dersh, Devin. Li, Jiang Yuan. Hemani, Humza. Lavorando, Maya. Bartoszek, Robert. Amses, Kevin R. Jain, Ankita. Minehart, Janna. Ho, Matthew. Ramirez-Fernandez, Angel. Paruzzo, Luca. Shestov, Max A. Camerini, Elena. Peters, Fleur S. Huang, Xiao. Loren, Alison W. Woyach, Jennifer A. Goronzy, Jorg Josef. Kater, Arnon P. Ruella, Marco. Byrd, John C. Powell, Daniel J., Jr. Gill, Saar I. Porter, David L. Schuster, Stephen J. Bushman, Frederic D. Siegel, Donald L. Levine, Bruce L. June, Carl H. Frey, Noelle V. Cohen, Adam D. Garfall, Alfred L. Long, Meixiao. Maus, Marcela V. Weng, Nan-Ping. Diorio, Caroline. Fraietta, Joseph A. T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia. , Blood.: 2026
Woyach, Jennifer A. Popovic, Relja. Rossi, Emily L. Singh, Sanjana. Oki, Toshihiko. Rosenberg, Tanya S. Qian, Chen. Moran, Michael. Liu, Zihuan. Boyer, Michelle. Jones, Jeffrey. Furman, Richard R. Wierda, William. Gotlib, Jason. Schuster, Stephen J. Chyla, Brenda. Davids, Matthew S. Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up. , Am J Hematol., 101(7): 2026,1516-1521
Ma, Nian. Bose, Dipayan. Svoboda, Jakob. Chong, Elise A. Schuster, Stephen J. Robertson, Erle S. FGFR2 is an oncogenic driver critical for successful human gammaherpesvirus latent infection and oncogenesis. , Proc Natl Acad Sci USA., 123(30): 2026
Wierda, William G. Dorritie, Kathleen A. Gauthier, Jordan. Nath, Rajneesh. Kipps, Thomas J. Riedell, Peter A. Eradat, Herbert A. Kenderian, Saad S. Kharfan-Dabaja, Mohamed A. Shah, Nirav N. Solomon, Scott R. Stephens, Deborah M. Ermann, Daniel A. Arnason, Jon E. Deol, Abhinav. Feldman, Tatyana A. Babis Andreadis, Charalambos. Ghosh, Monalisa. Ma, Shuo. Schuster, Stephen J. Gergis, Usama. Vose, Julie M. Soumerai, Jacob D. van Besien, Koen. Tuazon, Sherilyn A. Perna, Serena K. Ou, San-San. Ananthakrishnan, Revathi. Rane, Neha. Papp, Eniko. Ansari, Sahar. Thompson, Ethan G. Okal, Abood. Peiser, Leanne. Chen, Yizhe. Sengupta, Sanhita. Ray, Pradipta Ranjan. Wang, Jixian. Siddiqi, Tanya. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. , Blood.: 2026
Baron, Jonathan A. Chelius, Monica. Singh, Gurbani. Schad, Michael D. Berger, Melanie. Chong, Emeline R. Thomas, Colin J. Carter, Jordan S. Cook, Michael R. Nasta, Sunita D. Landsburg, Daniel J. Barta, Stefan K. Svoboda, Jakub. Schuster, Stephen J. Yegya-Raman, Nikhil. LaRiviere, Michael J. Plastaras, John P. Chong, Elise A. Hubbeling, Harper. Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas. , Clin Lymphoma Myeloma Leuk.: 2026
Ruella, Marco. Paruzzo, Luca. Chong, Emeline R. Chong, Elise A. Landsburg, Daniel J. Nasta, Sunita D. Devi, Pooja. Michener, Peter. Stella, Federico. Carturan, Alberto. Napier, Ellen B. Van Deerlin, Vivianna M. Porazzi, Patrizia. Levine, Bruce L. Frey, Noelle. Porter, David L. Fraietta, Joseph A. Svoboda, Jakub. June, Carl H. Schuster, Stephen J. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. , N Engl J Med., 394(24): 2026,2440-2448
Bartlett, Nancy L. Sehn, Laurie H. Assouline, Sarit. Giri, Pratyush. Kuruvilla, John. Schuster, Stephen J. Yoon, Sung-Soo. Fay, Keith. Hess, Georg. Dreyling, Martin. Gutierrez, Norma C. Cybulski, Eva. Sabalvaro, Fidelis. Penuel, Elicia. Teodoro, Vanda. Tracy, Samuel. Kuruvilla, Denison. Chen, Joseph. Wiebking, Volker. Wei, Michael C. Budde, L Elizabeth. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. , Am J Hematol., 101(5): 2026,986-997
Schneider, Michael. Paruzzo, Luca. Stella, Federico. Noll, Julia Han. Ho, Matthew. Babatunde, Victor. Ho, Bianca. Devi, Pooja. Chong, Elise A. Barta, Stefan K. Nasta, Sunita D. Svoboda, Jakub. Carter, Jordan. Cook, Michael R. Hossain, Nasheed M. Thomas, Colin J. Patel, Vrutti. de Souza, Vitor B. Alkhatib, Mohannad H. Li, Ziyu. Tan, Melody. Michener, Peter. Guruprasad, Puneeth. Imparato, Antonio. Carturan, Alberto. Porazzi, Patrizia. Fraietta, Joseph A. Schuster, Stephen J. Maillard, Ivan. Ruella, Marco. Landsburg, Daniel J. Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy. , Nat Commun., 17(1): 2026,6486
